Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 11;12(5):e0173222. doi: 10.1371/journal.pone.0173222

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Rojas et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 2 — A+B: CFDA SE cell tracer positive iPSC-CM grafts 7 days after intramyocardial transplantation: Adjacent to the host myocardium iPSC-CMs align in a parallel, longitudinal fashion and exhibit sarcomeric structures (arrows). Within central portions of broader grafts (approximately > 200 μm) they maintain a small, round shape (* in A). In the infarct penumbra iPSC-CMs lie in close proximity to host CMs (arrowheads in B1), occasionally with direct cell contact (arrowheads in the bottom right corner of B1). Inside the infarct area iPSC-CMs are typically surrounded by infiltrating host cells (arrowheads in B2). Tissue disruption during histological preparation (* in B1+2) indicates loose cell adhesion within iPSC-CM grafts. C+D: CFDA SE cell tracer positive iPSC-CM graft 28 days after intramyocardial transplantation: The cell tracer remains visible 28 days after engraftment, but iPSC-CMs develop an amorphic appearance. Sarcomeric structures are not observed. Vacuoles form during histological preparation (* in C). A+D: brightfield overlay. Scale bars: 400μm.